Thymosin Beta-4 (TB-4, full-length)
43-amino-acid actin-sequestering peptide
At a glance
What it is: 43-amino-acid actin-sequestering peptide.
Primary research applications:
- Ophthalmology (dry eye, corneal healing, Phase 2 evidence)
- Cardiac repair (investigational)
- Claimed: broader tissue regeneration
Editorial summary: Thymosin Beta-4 is the 'full-length parent' of TB-500, and, unlike TB-500, it has been studied in real Phase 2 human trials, most consistently in ophthalmology. The therapeutic story for cardiac and systemic repair is still preclinical.
What is Thymosin Beta-4?
Thymosin Beta-4 is a 43-amino-acid peptide found ubiquitously in mammalian cells, where it sequesters actin monomers and participates in cell migration, tissue repair, and angiogenesis. Recombinant TB-4 (RegeneRx's RGN-259 for ophthalmology, RGN-352 for cardiac applications) has been tested in humans.[1]
Mechanism of action
Key activities:
- Sequesters actin monomers, modulating cytoskeleton
- Promotes cell migration to injury sites
- Angiogenesis
- Anti-inflammatory and anti-apoptotic effects
What the research shows
The peer-reviewed literature on Thymosin Beta-4 is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity, supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Improves dry eye and corneal healing (topical) | Phase 2 RCTs | Supported |
| Promotes cardiac repair post-MI in humans | Preclinical and early human work | Preliminary |
| Is equivalent to TB-500 when administered systemically | TB-500 is a shorter fragment; equivalence not established | Uncertain |
Reported user experiences
How the research describes administration
Topical ophthalmic formulations in clinical trials; subcutaneous and intravenous routes in cardiac and systemic research.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness; these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Thymosin Beta-4 is a real, legitimate drug candidate in ophthalmology and regenerative medicine with Phase 2 human data. It is notably different from the grey-market TB-500 fragment, which borrows TB-4's reputation without matching its clinical substantiation.
Frequently asked questions
Is TB-4 the same as TB-500?
No. TB-4 is the full 43-amino-acid molecule with a real clinical development program. TB-500 is a 17-amino-acid synthetic fragment sold as a 'research chemical'.
Is TB-4 approved?
Not as of early 2026. Phase 2 and Phase 3 work has been primarily in ophthalmology (RGN-259).
Why haven't I heard of RGN-259?
Development has been slower than comparable programs. Regulatory filings for corneal indications may lead to approval in coming years, but timelines have historically slipped.
References
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a Phase 2 randomized trial. Cornea. 2015;34(5):491-6. https://pubmed.ncbi.nlm.nih.gov/25811720/